Boston Type 1 Keratoprosthesis for Iridocorneal Endothelial Syndromes

Phillips, Donald A.; Goins, Kenneth M.; Greiner, Mark A.; Alward, Wallace L.M.; Kwon, Young H.; Wagoner, Michael D.

doi:10.1097/ico.0000000000000616

Cited by 8 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19][20] Prophylactic antibiotics, antiseptics, and antifungal agents have been used to reduce microbial colonization of the ocular surface and the associated risk of microbial keratitis and/or endophthalmitis. [21][22][23][24][25] There is no evidence-based consensus on the composition or duration of an optimal postkeratoprosthesis prophylactic regimen. 5,[17][18][19][20][21][22][23][24][25] The prolonged use of soft contact lenses may be associated with an increased risk of gram-negative keratitis, 26,27 especially in this population with a high burden of ocular surface disease (OSD).…”

mentioning

confidence: 99%

Microbial Keratitis and Endophthalmitis After the Boston Type 1 Keratoprosthesis

Wagoner

Welder

Goins

et al. 2016

Cornea

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Microbial Keratitis and Endophthalmitis After the Boston Type 1 Keratoprosthesis

Wagoner

Welder

Goins

et al. 2016

Cornea

Self Cite

View full text Add to dashboard Cite

show abstract

“…Boston type 1 keratoprosthesis is an option in patients who have had failed allogenic transplants. 64 Four cases have been reported, three of which had an improved visual acuity of 6/30 Snellen equivalent 4 years postoperatively, with all grafts being retained in situ. As expected, glaucomatous progression is a known complication along with retroprosthetic membrane formation, 64 both of which may require surgical intervention.…”

Section: Corneal Surgical Managementmentioning

confidence: 99%

Iridocorneal endothelial syndrome: clinical perspectives

Walkden¹,

Au²

2018

OPTH

View full text Add to dashboard Cite

This article aims to review the clinical management strategies available for the rare iridocorneal endothelial syndrome. The different clinical variations as well as the imaging techniques available to aid diagnosis are discussed. We then present the evidence available to help the reader to understand how the condition can be managed medically and also the important surgical aspects of treatment. This involves raised intraocular pressure management in addition to the visual management options of partial or full thickness keratoplasty. We hope that this review provides an exhaustive but also succinct review of the literature available on what is a rare and difficult condition to treat.

show abstract

“…1 Other less common indications for Boston KPro type I reported in some case series included primary congenital glaucoma with concomitant corneal oedema, Aniridia, iridocorneal endothelial syndrome and gelatinous drop-like corneal dystrophy but the reported numbers are small. [3][4][5][6] A second design, the Boston KPro type II, in which the optic is implanted through the closed eyelid, was designed for severe end-stage ocular surface disease. 7 This was an attempt to replace OOKP so surgery can be done in a single stage with no requirement for a suitable tooth but the retention and visual results are no match.…”

mentioning

confidence: 99%